Novartis announced the construction of a 35,000‑square‑foot radioligand therapy (RLT) manufacturing plant in Winter Park, Florida, as the fourth U.S. site in its RLT network. The facility is part of the company’s $23 billion U.S. investment program and is slated to become operational in 2029, expanding domestic production capacity for its two FDA‑approved RLT treatments, Pluvicto and Lutathera, and future pipeline products.
The new plant follows existing U.S. RLT sites in Indiana, New Jersey, and California. By adding a fourth facility, Novartis aims to meet growing demand for its high‑precision oncology therapies, which deliver targeted radiation directly to cancer cells. The expansion also positions the company to scale production of upcoming pipeline candidates, reinforcing its leadership in the rapidly expanding RLT market.
"Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients," said Vas Narasimhan, Novartis CEO. "Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing U.S. manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them."
The investment reflects a strategic response to the time‑sensitive nature of RLT production, which requires proximity to treatment centers and robust supply chains. By expanding capacity, Novartis reduces the risk of bottlenecks, supports higher volumes of Pluvicto and Lutathera, and creates a platform for future RLT candidates. The move also signals confidence in sustained demand for precision oncology therapies and a commitment to keeping key products manufactured domestically.
Market reaction to the announcement has been positive, with Novartis’ stock reaching an all‑time high of $142.27 earlier in the week and analysts upgrading the company to an Equal‑Weight rating. The optimism reflects the company’s strong financial performance in recent quarters, reaffirmed guidance, and the $23 billion U.S. investment program, which investors view as a clear indicator of long‑term growth strategy.
The Florida facility underscores Novartis’ focus on scaling its RLT portfolio and securing a resilient supply chain, positioning the company to capture a larger share of the growing precision‑oncology market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.